NASDAQ:ACOR

Acorda Therapeutics - ACOR News Today

$0.92

-0.03 (-3.16%)

(As of 02/1/2023 12:00 AM ET)

Add

Compare

Today's Range: $0.90
▼
$0.96
50-Day Range: $0.52
▼
$1.00
52-Week Range: $0.26
▼
$2.29

Volume: 136,437 shs
Average Volume: 305,645 shs
Market Capitalization: $22.34 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Institutional Ownership

Get Acorda Therapeutics News Delivered to You Automatically

ACOR Media Mentions By Week

ACOR Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

ACOR
News Sentiment
▼
0.63

0.69
▲
Average
Medical
News Sentiment

ACOR News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

ACOR Articles
This Week
▼
2

1
▲
ACOR Articles
Average Week

Source

Source	Headline
	Acorda Therapeutics to Present at Sequire Biotechnology Conference finance.yahoo.com - January 31 at 8:25 PM
	StockNews.com Upgrades Acorda Therapeutics (NASDAQ:ACOR) to "Buy" americanbankingnews.com - January 30 at 4:50 AM
	Short Interest in Acorda Therapeutics, Inc. (NASDAQ:ACOR) Decreases By 8.1% americanbankingnews.com - January 24 at 7:59 AM
	Methyl Salicylate Patches Market Register to Growth by 2023-2027 \| Global Revenue and Key Dynamics with Industry Segments marketwatch.com - January 23 at 2:59 PM
	Repeat Expansion Disorders Treatment Market 2023 Expected to Witness the Highest Revenue Growth Over Forecast to 2029 marketwatch.com - January 17 at 7:35 AM
	Acorda Therapeutics Announces New Agreement with Catalent for Long-Term Global Supply of INBRIJA® finance.yahoo.com - January 5 at 6:29 PM
	Acorda Therapeutics Announces Revised Long-Term Financial Guidance finance.yahoo.com - December 22 at 11:04 AM
	Acorda Therapeutics gets Nasdaq delisting notice, plans to appeal decision msn.com - December 21 at 5:45 AM
	Acorda Therapeutics Receives Nasdaq Listing Determination Letter and Plans to Request a Hearing finance.yahoo.com - December 20 at 8:22 PM
	Spinal Cord Trauma Treatment Market 2023 : Manufacturers Strategies, Share Estimation, Future Demand and Regional Growth Dynamics 2028 marketwatch.com - December 9 at 11:05 AM
	Acorda Edges up on Making Interest Payment baystreet.ca - December 5 at 3:34 PM
	Acorda Therapeutics Makes December 2022 $6.2 Million Interest Payment on Secured Debt in Cash finance.yahoo.com - December 5 at 9:02 AM
	Acorda Therapeutics Third Quarter 2022 Earnings: US$0.57 loss per share (vs US$2.43 loss in 3Q 2021) finance.yahoo.com - November 19 at 7:15 PM
	Acorda Therapeutics Announces Passage of Reverse Stock Split Proposal at its Special Meeting of Stockholders finance.yahoo.com - November 11 at 12:47 PM
	How Is The Market Feeling About Acorda Therapeutics? msn.com - November 9 at 5:59 PM
	Acorda Therapeutics Reports Third Quarter 2022 Financial Results finance.yahoo.com - November 1 at 9:51 PM
	Acorda Therapeutics supplies long-term guidance and business plan in preparation for shareholders meeting proactiveinvestors.com - November 1 at 9:57 AM
	Acorda Therapeutics shares fly after it provides fresh revenue guidance proactiveinvestors.com - November 1 at 9:57 AM
	Acorda Therapeutics Provides Long-Term Business Plan and Financial Guidance finance.yahoo.com - October 27 at 4:55 PM
	Acorda Third Quarter 2022 Update: Webcast/Conference Call Scheduled for November 1, 2022 finance.yahoo.com - October 25 at 4:58 PM
	Acorda Shareholders Invited to Virtual Q&A with CEO Ron Cohen, M.D. finance.yahoo.com - October 21 at 7:22 AM
	Why Ericsson Shares Are Trading Lower? Here Are 56 Stocks Moving In Thursday's Mid-Day Session msn.com - October 20 at 4:06 PM
	ISS, Glass Lewis, and Egan-Jones Recommend that Acorda Stockholders Vote FOR the Proposal to Implement a Reverse Stock Split finance.yahoo.com - October 19 at 7:05 AM
	Acorda Therapeutics Will Not Use Shares for December 2022 $6.2 Million Interest Payment on Secured Debt finance.yahoo.com - October 18 at 10:05 AM
	Acorda Shares Surge Premarket on Ampyra Arbitration Win >ACOR marketwatch.com - October 17 at 8:30 AM
	Acorda Announces $16.5 Mln Award And Royalty/Supply Relief In AMPYRA Arbitration Case With Alkermes markets.businessinsider.com - October 16 at 10:25 PM
	Acorda Withdraws Proposal To Raise Authorized Shares From Special Meeting Of Stockholders nasdaq.com - October 10 at 11:45 AM
	Acorda Therapeutics Withdraws Proposal to Increase Authorized Shares from Special Meeting of Stockholders finance.yahoo.com - October 10 at 6:44 AM
	Defence Therapeutics Inc.: Defence Therapeutics Applauds United States President Biden Cancer Moonshot Initiative finanznachrichten.de - September 23 at 4:56 PM
	Acorda Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference finance.yahoo.com - September 8 at 8:19 PM
	Acorda Enters License Agreement For Nepicastat nasdaq.com - August 29 at 9:14 AM
	Acorda Therapeutics Enters into License Agreement with Asieris Pharmaceuticals finance.yahoo.com - August 29 at 9:14 AM
	Acorda Therapeutics COO Lauren Sabella To Resign nasdaq.com - August 19 at 12:47 PM
	Acorda Therapeutics Announces Resignation of Chief Operating Officer finance.yahoo.com - August 19 at 12:47 PM
	Acorda Therapeutics, Inc. (ACOR) CEO Ron Cohen on Q2 2022 Results - Earnings Call Transcript seekingalpha.com - August 7 at 3:41 PM
	Acorda Therapeutics Misses Q2 EPS by $2.79 investing.com - August 7 at 12:10 AM
	Acorda Therapeutics Non-GAAP EPS of -$3.15, revenue of $31.05M seekingalpha.com - August 7 at 12:10 AM
	Acorda Therapeutics Reports Second Quarter 2022 Financial Results finance.yahoo.com - August 4 at 7:08 PM
	Acorda Therapeutics Inc Stock Quote ACOR morningstar.com - July 30 at 6:38 AM
	Acorda Second Quarter 2022 Update: Webcast/Conference Call Scheduled for August 4, 2022 finance.yahoo.com - July 28 at 6:19 PM
	Nano-cap biotech Acorda surges 50% on drug launch in Germany seekingalpha.com - June 16 at 6:09 PM
	Why Acorda Therapeutics Shares Gaining Today? finance.yahoo.com - June 16 at 1:08 PM
	Esteve Launches INBRIJA® in Germany finance.yahoo.com - June 16 at 8:07 AM
	Acorda Therapeutics, Inc. Provides Notice of Data Privacy Event markets.businessinsider.com - June 14 at 9:02 PM
	Acorda Therapeutics Now the Least Expensive vs. Cardano This Year nasdaq.com - May 18 at 6:55 PM
	Acorda Therapeutics, Inc. 2022 Q1 - Results - Earnings Call Presentation seekingalpha.com - May 14 at 6:52 PM
	Acorda partners with Biopas to sell Parkinson's disease therapy in Latin America seekingalpha.com - May 11 at 7:32 PM
	Acorda Therapeutics and Biopas Laboratories Announce Agreement to Commercialize INBRIJA® in Latin America finance.yahoo.com - May 11 at 7:32 PM
	Acorda Therapeutics Reports First Quarter 2022 Financial Results finance.yahoo.com - May 11 at 7:32 PM
	Acorda First Quarter 2022 Update: Webcast/Conference Call Scheduled for May 11, 2022 finance.yahoo.com - May 4 at 7:38 PM

Get Acorda Therapeutics News Delivered to You Automatically

This page (NASDAQ:ACOR) was last updated on 2/2/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Acorda Therapeutics - ACOR News Today

ACOR Media Mentions By Week

ACOR Media Sentiment

ACOR News Coverage

About MarketBeat

Popular Tools

Financial Calendars

Terms & Info